We investigated the presence of autoantibodies to baculovirusexpressed human recombinant 65-and 67-kD isoforms of glutamate decarboxylase (GAD65 and GAD67) in insulin-dependent diabetes mellitus (IDDM). In the immunoprecipitation test using I35Slmethionine-labeled GADs antibodies to GAD65 were detected in 13/15 (87%) islet cell antibody (ICA)-positive and in 1/35 (2.9%) ICA-negative first-degree relatives of patients with IDDM, in 6/11 (54.5%) ICA-positive nondiabetic schoolchildren, and in 35/50 (70%) patients with newly diagnosed IDDM. GAD67 antibodies were positive only in five (33%) of the ICA-positive relatives (P < 0.05) and in nine (18%) IDDM patients at onset (P < 0.00001). After onset of IDDM antibodies to GAD65 and GAD67 declined but were still positive in 25 and 9.4% of subjects with long-standing IDDM (> 10 yr). In all study groups antibodies to GAD67 were only detected in GAD65 antibody-positive sera. An immunotrapping enzyme activity assay for GAD65 antibodies was positive in 64/75 (85.3%) of sera that were GAD antibody positive in the immunoprecipitation test (r = 0.870, P < 0.0001). In two (2.7%) sera GAD65 antibodies that block GAD enzyme activity were found. Our data suggest that antibodies to GAD65 but not to GAD67 represent sensitive markers for preclinical and overt IDDM. The immunotrapping assay here described represents a valuable technique for specific and sensitive screening for GAD antibodies. (J.
Introduction
Insulin-dependent diabetes mellitus (IDDM)' is strongly associated with the appearance of islet cell-specific autoantibodies, reflecting the autoimmune-mediated destruction ofthe pancre- 1 . Abbreviations used in this paper: AET, 2-aminoethylisothiouronium bromide; GAD65, GAD67, 65-and 67-kD; glutamate decarboxylase; ICA, islet cell antibodies; 64K, 64-kD islet cell protein; IDDM, insulindependent diabetes mellitus; IPT, immunoprecipitation test; ITA, immunotrapping assay; PLP, pyridoxal 5-phosphate. atic beta cells. Cytoplasmic islet cell antibodies (ICA) as well as antibodies to a 64-kD islet cell protein (64K) have been detected in 70-90% of individuals before and at the time ofdiagnosis of IDDM (1) (2) (3) (4) . In prospective studies only a subgroup of ICA-positive nondiabetic individuals, especially those with high ICA titers and complement-fixing ICA, developed IDDM (5, 6) . In first-degree relatives and ICA-positive nondiabetic subjects antibodies to the 64K antigen were detected early in the preclinical course of IDDM and were strongly correlated with rapid progression to overt diabetes (7, 8) . Therefore, the accurate determination ofantibodies to the 64K antigen would be of particular interest to identify subjects at high risk for the development ofIDDM. A large-scale detection of64K antibodies has been hampered by the laborious technique of the immunoprecipitation of[35S ] methionine-labeled islet cells preparations.
The target antigen ofthe 64K antibodies has been identified as the enzyme glutamate decarboxylase (GAD), which synthesizes y-aminobutyric acid (GABA) from glutamic acid (9) .
GAD exists at least in two different isoforms with molecular sizes of 65 kD (GAD65) and 67 kD (GAD67) encoded by two distinct genes (10, 11) . It was shown that GAD65 corresponds to the 64K antigen and both isoforms are recognized by sera from patients with IDDM ( 12, 13) . Population-based data on the frequency ofantibodies to human GAD67 are scanty. Thus, the importance of antibodies to GAD67 for IDDM is still unclear.
Because both isoforms of GAD are expressed in brain neurons ( 12, 13 ) several studies used brain preparations to determine antibodies to GAD by an immunotrapping enzyme activity assay (ITA) (14) (15) (16) . In contrast to 64K antibodies, antibodies to GAD, as measured in the ITA, were detected in only 25-37% of newly diagnosed patients with IDDM. It has been suggested that these controversial data might be due to differences in the sensitivity of the assays or that only a part of the immunoreactivity to the 64K islet protein is directed to GAD. In none ofthese reports has a direct comparison ofthe immunoprecipitation test and the ITA been performed to address this question.
In the present study human recombinant GAD expressed in the baculovirus system was used to determine autoantibodies to GAD65 and GAD67. We analyzed for the first time the prevalence ofantibodies to GAD65 and GAD67 in individuals at high risk for IDDM, at the onset ofthe disease, and in patients with a long duration of IDDM. In our approach we compared the results of the conventional immunoprecipitation test with the GAD immunotrapping enzyme activity assay in individual sera. This made it possible for us to determine antibodies which block GAD enzyme activity and evaluate the diagnostic value of the different immunoassays regarding the detection of antibodies to GAD.
Methods
Human sera. We studied sera from 50 patients with IDDM, obtained within the first month of diagnosis, and 77 sera from patients with a duration of IDDM from 0.5 to 40 yr. In addition, subjects at high risk for the development of IDDM were evaluated for GAD antibodies. We assayed GAD antibodies in 11 persistently ICA-positive nondiabetic schoolchildren without a family history of IDDM from the UlmFrankfurt population study (8, 17, 18) 6 h and then preabsorbed with protein A-Sepharose (Pharmacia Inc., Freiburg, Germany). 100 Ml of the precleared extracts were precipitated with 25 Ml test serum, followed by an adsorption of the immunocomplexes on protein A-Sepharose. After extensive washing the bound proteins were eluted with 65 mM Tris/HCI, pH 6.8; 2% SDS; and 5% mercaptoethanol and analyzed by fluorography. Fluorograms were analyzed by densitrometry (LKB Ultroscan; Pharmacia Inc.). In each experiment a positive and a negative reference serum were included as internal controls. Peak areas compared with the positive serum were taken as a measure of the GAD antibody level and expressed in percent of the positive standard serum. Values above mean + 3 SD of 60 control subjects were considered positive. Using this assay in the First GAD Antibody Workshop, we achieved a specificity of 100%, asensitivity of 83.3%, and a validity of 87.5%.
ITA. The particulate fraction of Sf9 cells expressing GAD65 was resuspended in buffer A, pH 7.0, supplemented with 1% Triton X-100 for 2 h at 4°C. After centrifugation at 33,000 gfor 30 min, the supernatant was used to perform the ITA. 100 Ml of serum were incubated with 200 Ml reconstituted protein A-Sepharose beads for 2 h at 20'C. The beads were washed four times with 50 mM potassium phosphate, pH 7.0; 1 mM EDTA; 1 mM AET; 0.2 mM PLP; and 0.5% Triton X-100, 400 AI of MF (corresponding to a GAD activity of0.5 mU) was added for 12 h at 4VC. After another washing step, 400 AI 50 mM potassium phosphate buffer, pH 7.0, with 1 mM EDTA, 1 mM AET, 1 mM glutamic acid, 0.2 mM PLP (buffer B) was added, and the samples were divided into two aliquots and the precipitated enzymatic GAD activity was determined. The immunotrapped GAD activity was calculated by subtracting the background counts using PBS instead ofserum and was expressed in AU immunotrapped by 50 ,A serum. Sera were considered GAD antibody positive if the immunoprecipitated GAD activity was above the mean + 3 SD of 60 control subjects.
Determination ofGAD enzyme activity. GAD activity was analyzed using a modification of the protocol described by Miller et al. (21 ) . Aliquots of homogenates or immunocomplexes were diluted in buffer B to a total volume of 200 AL with a final concentration of 1 mM/liter L-glutamic acid and a specific radioactivity of L[ 1-'4C]glutamic acid (Amersham Corp., Braunschweig, Germany) of 500 MCi/mmol for assaying of GAD activity in the cell extracts and 1,000 ,Ci/mmol in the ITA, respectively. After adding the reaction mixture into glass tubes, a filter paper soaked with 50 Al 1 M hyamine hydroxide was placed into the tubes. The tubes were closed and incubated for 1 h at 37°C. The reaction was stopped by injecting 1 ml 5 N sulphuric acid followed by an equilibration period of 1 h to allow complete adsorption of released '4CO2. Then the "4CO2 trapped to the filter paper was measured in a liquid scintilation counter. GAD enzyme activity was expressed in U/mg protein. One unit was defined as the formation of 1 Mmol C02/min under standard assay conditions. Statistical analysis. The significance of differences between observations was tested using the Wilcoxon test, the chi-square test with Yates' correction, or the Fisher's exact test, where appropriate. The correlations ofantibody levels were tested by linear-regression analysis.
Results
Autoimmunity to GAD in IDDM is mainly directed to GAD65. Human recombinant GAD65 and GAD67 were highly expressed in a baculovirus system. The enzymatic activity of 1 2 3 4 5 6 94-67-3m (lanes 1-4) and GAD67 (lanes 5-8) were immunoprecipitated with two sera from newly diagnosed IDDM patients (patient 1, lanes I and 6, patient 2, lanes 2 and 5) and a serum from a control subject (lanes 3 and 7 (18%) subjects (P < 0.00001). In addition, antibodies to (ATTC no. HB 184; reference 22) and recombinant GAD67 GAD67 were observed only in GAD65-positive sera. At the onwas precipitated by the K-2 antiserum (23), which binds to the set of IDDM, ICA were positive in 38 (76%) sera (mean ICA 67-kD isoform ofGAD (Fig. 1) The prevalence of each of the antibody specificities tested declined after the onset of IDDM (Table II) . After 0.5-2 yr, antibodies to GAD65 as well as ICA were decreased compared with newly diagnosed patients with IDDM (P < 0.05). IDDM patients tested up to 10 yr after onset of IDDM exhibited a highly significant reduction ofantibodies to GAD65 and ICA (P < 0.0005). In long-term diabetic patients ( 11-40 yr), the frequency of antibodies to GAD65 (8/ 32, 25.0%) was slightly increased compared with the IDDM patients 2-10 yr after onset of IDDM. The prevalance of antibodies to GAD67 declined from 18% at diagnosis to 9.4% after long duration of IDDM, but this did not reach the level of significance.
High prevalance of GAD antibodies in subjects with increased risk for IDDM. 6 of 11 (54.5%) nondiabetic individuals with persistent ICA (mean 52±45 JDF-U, range 10-160) without a family history of IDDM possessed antibodies to GAD65. All of these six sera had been found 64K antibody positive in the IPT using labeled islets (8) . 13 (86.7%) of 15 first-degree relatives with ICA levels > 40 JDF-U (mean 331±211 JDF-U, range 80-640) had antibodies to GAD65, whereas only 5 (33.3%) ofthem were GAD67 antibody positive (P < 0.05). The level ofthe GAD65 antibodies ( 143±85%) was significantly increased compared with new onset IDDM patients (74±66%) (P < 0.005). In 1 of 35 (2.9%) ICA-negative relatives, antibodies to GAD65 were observed. Antibodies to GAD67 were only detected in GAD65 antibody-positive sera.
Antibodies to GAD67 were negal gree relatives and in 11 ICA-po The ITA reveals GAD antibodies ofhigh specificity and sensitivity. All sera from the different study groups were tested in our newly developed ITA using recombinant GAD65. The mean + 1 SD of the immunotrapped GAD activity of 60 control subjects was 2.32 + 1.46 (range 0.44-5.77 AU). Binding of > 6.7 MU (mean + 3 SD) was considered as immunotrapped GAD65 antibody positive. The intra-and interassay coefficients of variation were 10.2% (n = 8) and 15.7% (n = 8), respectively. Antibodies to GAD65, detected by the ITA were found in 64 of 75 (85.3%) of the GAD65 antibody-positive subjects, as characterized in the IPT (Table 1 ). The mean level of the positive subjects was 71±75 uU (range 6.8-277.0 ,U). There was a strong correlation between the levels of GAD65 antibodies determined in the IPT and the level of immunotrapped GAD activity (Fig. 2) (r = 0.870, P < 0.0001). None of the GAD65 antibody-negative subjects or of the normal controls exceeded the normal range (mean + 3 SD of controls). Compared with the conventional IPT as the gold-standard technique, the ITA achieved values of 100% for specificity and 87.2% for sensitivity.
GAD-blocking antibodies appear in only a minority ofindividuals. GAD antibodies that block the enzyme activity were detected by analyses ofthe results ofthe IPT compared with the ITA in individual sera. Regarding 11 GAD65 antibody-positive sera, which were negative in the ITA, 9 turned out to be just weakly GAD65 antibody positive (GAD65 antibody level 13-17% ofthe reference serum) (Fig. 2) . Thus, only 2 of 75 (2.7%) GAD65 antibody-positive sera may possess high titers of GAD antibodies that inhibited the enzyme activity. Discussion tive in all ICA-negative first-deAntibodies to the 64K islet cell protein have been described as )sitive schoolchildren.
an early and reliable serological marker to predict future development of IDDM in nondiabetic individuals. The identification ofthe 64K protein as GAD and the recognition of at least two isoforms have raised the question as to which isoform would be the major antigen in the natural history ofIDDM. To address this question we expressed human GAD65 and GAD67 in the baculovirus system to produce a homogeneous source of native antigens. This allowed us to overcome the disadvantages of the antigen shortage, differences in the cell preparation, and antigen purity, which were critical to the conventional IPT using isolated islets.
The observed prevalence of 86.7% of antibodies to GAD65 in ICA-positive relatives and 70% in patients with recent onset of IDDM was similar to the frequency of 64K antibodies using labeled islets (4, 24) . In addition, we detected antibodies to GAD65 in all 64K antibody-positive schoolchildren (8) . These findings support the contention that GAD65 is identical to the 64K islet cell protein (9, 13) . Consistent with studies suggesting that antibodies to the 64K antigen indicate an increased risk for the development of IDDM (7), we found that three of lies (% reference serum) the six GAD65 antibody-positive schoolchildren developed overt IDDM after a follow-up of 16-30 mo (8) . In our study Lnd the conventional IFT for the the prevalence and levels ofantibodies to GAD65 were higher in nonstrated. (9) . In contrast to the present data, Kaufman et al. ( 13 ) and Deaizpurua et al. (25) reported on antibodies to GAD67 in 9 of 12 and in 7 of 9 preclinical subjects as well as in 3 of 3 and in 6 of 13 patients with IDDM, respectively. Various explanations could be found for this disagreement. First, these authors used bacterially expressed rat or mouse GAD67. Despite a high homology of rat, mouse, and human GAD67 ( 11 ) the discrepancy could be due to the species differences, since different antigenic enzyme forms of GAD have been described (26, 27 immunoreactivity. Direct epitope studies will be required to fully support this hypothesis. Analogous to ICA, the prevalence of antibodies to GAD65 and GAD67 declined in the first years after the onset of IDDM. This has also been shown for 64K antibodies (31 ) . However, in our study, antibodies to GAD65 were still detectable in 25% of subjects with a long duration ofIDDM. As initially reported by Kaufman et al. ( 13) , we here observed that six ofeight patients with long-standing IDDM and antibody reactivity to GAD65 had a peripherial diabetic neuropathy (data not shown). The high frequency of GAD antibodies in these patients could be explained by the reappearance ofantibodies to GAD caused by a repeated presentation of GAD to the immune system by the affection of GABA synthesizing neurons during the development of diabetic neuropathy (32) .
After the identification of GAD as a target antigen in IDDM, antibodies to GAD were detected in several studies by measuring the immunotrapping enzyme activity. The prevalence of antibodies to GAD was reported to be as low as 25-38% using rat (14) , pig (15) , or human brain preparations ( 16) . On the basis ofthe studies mentioned above, it could not be decided whether the low prevalence ofantibodies to GAD in the ITA compared with the IPT is due to differences in the source of antigen or to the lower sensitivity of the ITA. In our newly developed ITA using human GAD65, we can detect antibodies in > 85% of sera that were positive in the IPT. For the first time we demonstrate a strongly positive correlation between the level of antibodies in both assays. With this new assay the ITA achieved a 100% specificity and a high sensitivity that was only slightly decreased compared with the standard IPT. It is important to emphasize that out of75 GAD antibody positive sera only 2 sera had high levels in the IPT, being repeatedly negative in the ITA. This suggests the presence of GAD binding antibodies inhibiting the GAD enzyme activity. Furthermore, nine sera with low antibody levels in the IPA were negative in our ITA. These negative results may be explained by the lower sensitivity ofthe measurement ofenzyme activity in the ITA compared with the fluorography technique. As we cannot exclude the presence of antibodies that block GAD enzyme activity in these sera, our data at least indicate that GADblocking antibodies are only present in a minority of patients with IDDM.
In conclusion, antibodies to GAD65 are valuable serological markers for preclinical and overt IDDM, whereas antibodies to GAD67 may be of minor importance. Because GAD-blocking antibodies appear only in a minority of patients with IDDM, the ITA represents a valuable tool for the detection ofantibodies to GAD with the advantage ofeasy performance and quantitative measurement ofthe autoantibodies. The availability of human recombinant GAD facilitate specific and sensitive screening for antibodies to GAD on large scale and may be useful to determine the role of GAD in the development of IDDM.
